# A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

> **NCT05143970** · PHASE1 · RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 27 (estimated)

## Conditions studied

- Metastatic Cancer
- Metastatic Breast Cancer
- Metastatic Pancreatic Cancer
- Metastatic Gastric Cancer
- Metastatic Lung Cancer
- Metastatic Ovary Cancer
- Oesophageal Cancer
- Endometrial Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB

## Key facts

- **NCT ID:** NCT05143970
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-21
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143970, "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05143970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*